Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients

Obesity

Volumn 17, Issue 3, 2009, Pages 504-509

  Rosenson, Robert S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CCL2 PROTEIN, HUMAN; FENOFIBRATE; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ADULT; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CHEMOKINE CCL3; FEMALE; FIBRINOGEN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROCETOFEN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 60849116123     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.530     Document Type: Article

References (28)

1. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-397.
2. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
3. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-1737.
4. Schulze MB, Shai I, Rimm EB et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54: 534-539.
5. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001 ;60:349-356.
6. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: its role in health and disease. J Mol Med 2004;82:434-448.
7. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
8. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
9. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-1732.
10. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-Reactive Protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-674.
11. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007;30:1945-1951.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ;285:2486-2497.
13. Freedman DS, Otvos JD, Jeyarajah EJ et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem 2004;50:1189-1200.
14. Rosenson RS, Staffileno BA, Tangney CC. Effects of tourniquet technique, order of draw, and sample storage on plasma fibrinogen. Clin Chem 1998;44:688-690.
15. Han SH, Quon MJ, Kim J-A, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531-538.
16. Tsao T-S, Tomas E, Murrey HE et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J Biol Chem 2003;278: 50810-50817.
17. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653.
18. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005;28:1419-1424.
19. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-a activators. J Biol Chem 2000;275:36703-36707.
20. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063.
21. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1 RA in human leukocytes. Biochem Biophys Res Commun 2004;323:630-635.
22. Choi KC, Ryu OH, Lee KW et al. Effect of PPAR-α and -β agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005;336:747-753.
23. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001 ;280:E745-E751.
24. Chinettl G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR. Biochem Biophys Res Commun 2004;314:151-158.
25. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001 ;86:3815-3819.
26. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380.
27. Forst T, Hohberg C, Fuellert SD et al. Pharmacological PPARγ stimulation in contrast to β cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005;37:521-527.
28. Després J-P, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121 -2134.